Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176592 · ClinicalTrials.gov registry record · Phase 4
Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI
A Phase 4 study of Multiple Sclerosis, sponsored by University of Medicine and Dentistry of New Jersey.
- Completed
- Registry status
- Phase 4
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT00176592: Completed Phase 4 study of Multiple Sclerosis, sponsored by University of Medicine and Dentistry of New Jersey.
NCT00176592 is a Phase 4 study of Multiple Sclerosis that has completed, run by University of Medicine and Dentistry of New Jersey. The registered enrollment target is 75 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00176592, a Phase 4 study of Multiple Sclerosis, has completed, sponsored by University of Medicine and Dentistry of New Jersey.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This is the first comparison of efficacy of Betaseron and Copaxone for treatment of relapsing forms of MS.
Primary Outcome
Results are per patient mean number of lesions per scan. Results are per patient mean number of lesions per elapsed month. Contrasts types are: IFN 1b interferon beta 1b and GA glatiramer acetate.
Conditions Studied
Interventions
- DRUG Copaxone
- DRUG Betaseron
Study Locations (1)
New Jersey
- New Jersey Medical School - Newark
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2003-01 |
| Est. Completion | 2007-01 |
| Phase | Phase 4 |
What the finished NCT00176592 record still lists
NCT00176592 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Copaxone is the first listed.
NCT00176592 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT00176592 about?
NCT00176592 is a clinical study titled "Phase IV Study, Betaseron Versus Copaxone for Relapsing Remitting or CIS Forms of MS Using Triple Dose Gad 3 T MRI". This is the first comparison of efficacy of Betaseron and Copaxone for treatment of relapsing forms of MS.
What is the current status of trial NCT00176592?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 75 participants. The study started on 2003-01. Estimated completion is 2007-01.
What conditions does trial NCT00176592 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT00176592?
The interventions under investigation include: Copaxone (DRUG), Betaseron (DRUG).
Who is sponsoring clinical trial NCT00176592?
This trial is sponsored by University of Medicine and Dentistry of New Jersey, which has 88 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00176592 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00176592's enrollment target sits among peer trials
75 147th of 315 higher than 167 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 4
-
Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis
RECRUITING · Phase 4
-
Glucose Consumption in MS Using [F-18]FDG-PET
RECRUITING · Phase 4
-
Home Based Infusions for Ocrelizumab
RECRUITING · Phase 4
-
Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis
RECRUITING · Phase 4
-
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia